The most promising GHR-inhibiting compound, C#1, showed a 6-fold decrease in tumor growth in mice transplanted with the triple-negative mammary breast cancer cell line MDA-MM-231, at a dose of 1 mg/kg, three times weekly [11]. This evidence concerns the gene GHR and neoplasm.